Extended procedure has no oncological benefits over segmental resection in the treatment of non-metastatic splenic flexure colon cancer, a population-based cohort study and a single center’s decade-long experience
Updates in Surgery · 2024
DOI: 10.1007/s13304-024-01897-1 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Updates in Surgery, 2024. Verfasst von Xiaojie Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Union Hospital, Fujian Medical University, 29 Xin-Quan Road, Fuzhou, 350001, Fujian, People's Republic of China. xj…. Hauptthemen laut MEDLINE: Colonic Neoplasms, Colon, Transverse, Neoplasm Staging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Bethune Charitable Foundation, Fujian Association for Science and Technology, Joint Funds for the innovation of Science and Technology, Fujian province.
Abstract (Originalsprache)
To compare the oncological survival outcome between extended resections (ER) and segmental resection (SR) for non-metastatic splenic flexure tumors. A total of 10,063 splenic flexure colon cancers patients who underwent ER (n = 5546) or SR (n = 4517) from 2010 to 2018 were included from the Surveillance, Epidemiology, and End Results (SEER)-registered database. Additionally, we included 135 patients from our center who underwent ER (n = 54) or SR (n = 81) between 2011 and 2021. Survival rates were compared between groups. To reduce the inherent bias of retrospective studies, propensity score matching (PSM) analysis was performed. In the SEER database, patients in the ER group exhibited higher pT stage, pN stage, larger tumor size, and elevated rates of CEA level, perineural invasion, and tumor deposits compared to those in the SR group (each P < 0.05). The 5-year cancer-specific survival (CSS) rate was slightly lower in the ER group than in the SR group (79.2% vs. 81.6%, P = 0.002), while the 5-year overall survival (OS) rates were comparable between the two groups (66.2% vs. 66.9%, P = 0.513). After performing PSM, both the 5-year CSS and 5-year OS rates were comparable between the ER and SR groups (5-year CSS: 84.9% vs. 83.0%, P = 0.577; 5-year OS: 70.6% vs. 66.0%, P = 0.415). These findings were consistent in the subgroup analysis that included only patients with stage III disease or tumor size ≥ 7 cm. Furthermore, although the number of harvested lymph nodes was higher in the ER group compared to the SR group (14.4 vs. 12.7, P < 0.001), the number of invaded lymph nodes remained similar between the two groups (0.5 vs. 0.5, P = 0.90). Similarly, our center's data revealed comparable 3-year OS and 3-year disease-free survival (DFS) rates between the two groups. ER have no significant oncological benefits over SR in the treatment of non-metastatic splenic flexure colon cancer, even for locally advanced cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Colorectal Surgery, Union Hospital, Fujian Medical University, 29 Xin-Quan Road, Fuzhou, 350001, Fujian, People's Republic of China. xjwang363@163.com.
- Department of Colorectal Surgery, Union Hospital, Fujian Medical University, 29 Xin-Quan Road, Fuzhou, 350001, Fujian, People's Republic of China.
Förderung
- Bethune Charitable Foundation
- Fujian Association for Science and Technology
- Joint Funds for the innovation of Science and Technology, Fujian province
- Medical Science Research Foundation of Beijing Medical and Health Foundation
- Natural Science Foundation of Fujian Province
Zitieren
APA
Wang, X., Wang, Y., Zheng, Z., Chen, Z., Xie, Z., Lu, X., Huang, S., Huang, Y., & Chi, P. (2024). Extended procedure has no oncological benefits over segmental resection in the treatment of non-metastatic splenic flexure colon cancer, a population-based cohort study and a single center’s decade-long experience. Updates in Surgery. https://doi.org/10.1007/s13304-024-01897-1
Vancouver
Wang X, Wang Y, Zheng Z, Chen Z, Xie Z, Lu X, et al. Extended procedure has no oncological benefits over segmental resection in the treatment of non-metastatic splenic flexure colon cancer, a population-based cohort study and a single center’s decade-long experience. Updates in Surgery. 2024. doi:10.1007/s13304-024-01897-1
BibTeX
@article{Wang2024,
author = {Wang, Xiaojie and Wang, Yangyang and Zheng, Zhifang and Chen, Zhiping and Xie, Zhongdong and Lu, Xingrong and Huang, Shenghui and Huang, Ying and Chi, Pan},
title = {Extended procedure has no oncological benefits over segmental resection in the treatment of non-metastatic splenic flexure colon cancer, a population-based cohort study and a single center’s decade-long experience},
journal = {Updates in Surgery},
year = {2024},
doi = {10.1007/s13304-024-01897-1}
}
EUVIMED